Anxiety, restlessness, tremor, and headache.
Severe hypertension, which may result in intracranial hemorrhage, pulmonary edema, or myocardial necrosis or infarction.
Use with caution in patients intoxicated by halogenated or aromatic hydrocarbon solvents and anesthetics because these agents may sensitize the myocardium to the arrhythmogenic effects of epinephrine.
Tissue necrosis after extravasation or intra-arterial injection.
Aggravation of tissue ischemia, resulting in gangrene.
Anaphylactoid reaction, which may occur owing to the bisulfite preservative in patients with sulfite hypersensitivity.
Hypokalemia, hypophosphatemia, hyperglycemia, and leukocytosis may occur owing to the beta-adrenergic effects of epinephrine.
Use in pregnancy. FDA Category C (indeterminate). Epinephrine is teratogenic in animals, crosses the placenta, can cause placental ischemia, and may suppress uterine contractions, but these effects do not preclude its acute, short-term use for a seriously symptomatic patient (See Introduction in Section III).